Nuformix PLC (LON:NFX) said its chief executive Anne Brindley has decided to step down from her role.
The pharmaceutical development firm said Brindley will continue in her current position for the next six months and has committed to assist the company with an orderly transition for the period.
READ: Nuformix says drug pipeline is 'building momentum'
"Anne has been made an exceptional offer by another company which she wants to pursue. She is committed to ensuring the progress of the three assets in the Nuformix portfolio over the next six months and will continue to lead this process. In particular, managing the further preclinical work on NXP002 to deliver a more robust data package, the further research on NXP004 and concluding the licensing discussions on NXP001”, Nuformix non-executive chairman Alastair Riddell said in a statement.
"We will be very sorry to see Anne go but we wish her all the very best in her future pursuits. We look forward to providing further updates to shareholders on the development of the portfolio of assets in the coming months", Riddell added.